Poor Outcomes With +der(22)t(9;22) and −9/9p in Patients With Ph-Positive ALL Receiving Chemotherapy Plus a TKI
In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established. In a recent study the prognostic impact of individual ACAs was evaluated in 152 patients with Ph+ ALL receiving first-line intensive chemotherapy plus either imatinib […]
